[Can dexpanthenol prevent peritoneal adhesion formation? An experimental study].
BACKGROUND
Peritoneum has an intrinsic fibrinolytic activity that breaks the peritoneal adhesions. Ischemic peritoneal injuries interfere with this fibrinolytic activity. Local application of dexpanthenol, the alcohol form of pantothenic acid (vitamin B5) accelerates wound healing by increasing mitosis. We hypothesized that dexpanthenol would decrease peritoneal adhesions.


METHODS
In rats, antimesenteric border of cecum was abraded with gauze. No medication was given to the control group (n=15). Dexpanthenol was administered intraperitoneally (IP) (n=15, 25 mg/kg, before abdominal closure) or intravenously (IV) (n=15, 25 mg/kg, for 9 days after operation) in the experiment groups. On postoperative day 10, adhesions were graded; activities and concentrations of tissue plasminogen activator (tPA), plasminogen activator inhibitor type 1 (PAI-1), tPA/PAI-1 complex and hydroxyproline contents were determined in peritoneum.


RESULTS
Adhesion formation was decreased in IP dexpanthenol group compared with control group (p=0.034). tPA concentration and activity and tPA/PAI-1 complex levels were increased in the treated groups compared to controls. PAI-1 levels were similar among the three groups. Peritoneal hydroxyproline levels were lower in animals receiving IV dexpanthenol compared with control animals and in addition, they remained unchanged in IP dexpanthenol treated group (p=0.009, p=0.84, respectively).


CONCLUSIONS
Our results suggest that dexpanthenol administration through IP may reduce peritoneal adhesion formation probably by altering peritoneal fibrinolytic activity.
Akdeniz
Yusuf
Y
Department of General Surgery, Medicine Faculty of Süleyman Demirel University, Isparta, Turkey.
Tarhan
Omer Ridvan
OR
Barut
Ibrahim
I
D000818:Animals; D005342:Fibrinolysis / Q000187:drug effects*; D006909:Hydroxyproline / Q000378:metabolism; D007262:Infusions, Intravenous; D007274:Injections, Intraperitoneal; D008297:Male; D010205:Pantothenic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D010532:Peritoneal Diseases / Q000378:metabolism / Q000473:pathology*; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D000267:Tissue Adhesions / Q000378:metabolism / Q000473:pathology*; D010959:Tissue Plasminogen Activator / Q000378:metabolism; D014803:Vitamin B Complex / Q000008:administration & dosage / Q000494:pharmacology*; D014945:Wound Healing / Q000187:drug effects
D017395:Plasminogen Activator Inhibitor 1; D014803:Vitamin B Complex; D010205:Pantothenic Acid; C007288:dexpanthenol; D010959:Tissue Plasminogen Activator; D006909:Hydroxyproline